News
News Center
Jiuzhitang Introduces International Technology to Enter the Stem-Cell Pharmaceutical Market
来源：Shanghai Securities News
2018-09-17
Shanghai Securities News (Reporter Zhang Xue) – On September 14, Jiuzhitang, a traditional Chinese medicine pharmaceutical company, announced that its newly established Jiuzhitang Yonghe Qihang Fund has signed an investment agreement with Stemedica Cell Technologies Inc., a U.S.-based biotech firm. Under the terms of the agreement, Jiuzhitang Maker (Beijing) Cell Technologies Co., Ltd. will introduce cutting-edge stem-cell production technologies and a state-of-the-art manufacturing platform from one of the world’s leading stem-cell companies. Over the next three to five years, Jiuzhitang Maker plans to build a commercial-grade stem-cell production facility in Beijing’s Daxing Biomedical Industry Base, adhering to both U.S. and EU cGMP (current Good Manufacturing Practice) standards. This marks Jiuzhitang’s official entry into the research, clinical development, and industrialization of stem-cell-based therapies.
Li Zhenguo, Chairman of Jiuzhitang, stated that the company will leverage its strengths in the traditional Chinese medicine industry while capitalizing on global advancements in stem cell technology, focusing strategically on the regenerative medicine sector. Jiuzhitang aims to seamlessly integrate China’s time-honored traditional medical practices with cutting-edge stem-cell-based biotechnology, paving the way for an innovative growth path tailored specifically for this iconic Chinese pharmaceutical enterprise.
According to Li Zhenguo, Jiuzhitang Maker will collaborate with top domestic hospitals to conduct multi-center clinical trials. Building on Stemedica's promising clinical trial results, the company plans to advance stem-cell-based clinical research targeting neurological and cardiovascular diseases. Meanwhile, Jiuzhitang Maker has also signed cooperation agreements separately with Mexico’s Novastem Cell Technology Company and Kazakhstan’s ALTACO Cell Technology Company, aiming to jointly establish an internationalized stem-cell R&D platform.
Stem cells, also known as origin cells or "pluripotent cells," are a population of primitive cells with the unique abilities to self-renew, proliferate extensively, and differentiate into multiple cell types. These cells serve as progenitors capable of giving rise to various tissues and organs. Stem cells are celebrated in the medical community for their remarkable traits, including self-renewal, potent differentiation potential, low immunogenicity, and excellent tissue compatibility—earning them the title of "pluripotent cells."
Stem cell technology and its development have been increasingly popular in capital markets in recent years. Among U.S.-listed companies on the Nasdaq, stem cell-related stocks collectively hold a market value exceeding $30 billion. According to the "2018 China Stem Cell Medical Industry Analysis Report—In-Depth Market Analysis and Prospects Study," the global stem cell medical market had already reached $98.5 billion by 2018. Meanwhile, data from the Ministry of Health reveals that China's current stem cell market is valued at over 40 billion yuan, with a compound annual growth rate surpassing 50% between 2009 and 2016.
In recent years, China has steadily increased its investment and strategic planning in stem cell research—both in fundamental studies and translational applications. Stem cells have been designated as a key priority under the 2017 National Key R&D Program, and are prominently featured as a flagship area for support across several major policy initiatives, including the "13th Five-Year" National Science and Technology Innovation Plan, the National Strategy for Innovation-Driven Development, the National Plan for Building a Standardization System, and the Specialized Plan for Health and Wellness Science & Technology Innovation during the 13th Five-Year Period.
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy